Sarepta Therapeutics (SRPT) Short Interest Ratio & Short Volume $20.99 -0.82 (-3.76%) Closing price 04:00 PM EasternExtended Trading$21.02 +0.03 (+0.14%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Sarepta Therapeutics Short Interest DataSarepta Therapeutics (SRPT) has a short interest of 20.95 million shares, representing 23.20% of the float (the number of shares available for trading by the public). This marks a 40.98% increase in short interest from the previous month. The short interest ratio (days to cover) is 1.8, indicating that it would take 1.8 days of the average trading volume of 6.14 million shares to cover all short positions.Current Short Interest20,950,000 sharesPrevious Short Interest14,860,000 sharesChange Vs. Previous Month+40.98%Dollar Volume Sold Short$344.00 millionShort Interest Ratio1.8 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares97,713,000 sharesShort Percent of Float23.20%Today's Trading Volume6,067,467 sharesAverage Trading Volume6,137,997 sharesToday's Volume Vs. Average99% Short Selling Sarepta Therapeutics? Sign up to receive the latest short interest report for Sarepta Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartSRPT Short Interest Over TimeSRPT Days to Cover Over TimeSRPT Percentage of Float Shorted Over Time Sarepta Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/202520,950,000 shares $344.00 million +41.0%23.2%1.8 $16.42 7/15/202514,860,000 shares $270.60 million +1.2%N/A1.8 $18.21 6/30/202514,680,000 shares $251.03 million +48.4%16.2%2.8 $17.10 6/15/20259,890,000 shares $357.82 million +6.8%10.9%2 $36.18 5/31/20259,260,000 shares $349.29 million +4.9%10.5%2.5 $37.72 5/15/20258,830,000 shares $311.43 million +31.8%10.0%2.6 $35.27 4/30/20256,700,000 shares $418.08 million +1.2%N/A2.5 $62.40 4/15/20256,620,000 shares $360.26 million +8.5%7.5%3.5 $54.42 3/31/20256,100,000 shares $389.30 million +25.8%6.9%3.7 $63.82 3/15/20254,850,000 shares $471.37 million -4.2%5.5%3.9 $97.19 Get the Latest News and Ratings for SRPT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/28/20255,060,000 shares $540.16 million +2.9%5.7%6 $106.75 2/15/20254,920,000 shares $531.11 million -2.6%5.6%5.6 $107.95 1/31/20255,050,000 shares $574.29 million +1.4%N/A5.3 $113.72 1/15/20254,980,000 shares $594.26 million -2.9%N/A5.3 $119.33 12/31/20245,130,000 shares $623.76 million -8.2%N/A5.5 $121.59 12/15/20245,590,000 shares $691.54 million -4.0%N/A5.8 $123.71 11/30/20245,820,000 shares $776.04 million +15.5%N/A6 $133.34 11/15/20245,040,000 shares $526.88 million -10.0%N/A5.5 $104.54 10/31/20245,600,000 shares $705.60 million -1.1%N/A6.6 $126.00 10/15/20245,660,000 shares $700.31 million -8.6%N/A6 $123.73 9/30/20246,190,000 shares $773.07 million +0.7%N/A6.1 $124.89 9/15/20246,150,000 shares $766.60 million -5.8%N/A5.3 $124.65 8/31/20246,530,000 shares $886.64 million -3.0%N/A4.4 $135.78 8/15/20246,730,000 shares $897.38 million +0.2%N/A3.5 $133.34 7/31/20246,720,000 shares $955.85 million -8.3%N/A3.5 $142.24 7/15/20247,330,000 shares $1.12 billion -23.3%N/A3.9 $152.67 6/30/20249,560,000 shares $1.51 billion +1.1%N/A5.4 $158.00 6/15/20249,460,000 shares $1.16 billion +45.8%N/A5.7 $122.84 5/31/20246,490,000 shares $842.79 million -1.1%N/A5.1 $129.86 5/15/20246,560,000 shares $869.20 million +15.3%N/A7.3 $132.50 4/30/20245,690,000 shares $720.70 million +16.8%N/A6.2 $126.66 4/15/20244,870,000 shares $576.17 million +5.9%N/A5.8 $118.31 3/31/20244,600,000 shares $595.52 million -7.4%N/A4.5 $129.46 3/15/20244,970,000 shares $611.56 million +4.0%N/A4.6 $123.05 2/29/20244,780,000 shares $611.36 million -0.6%N/A4 $127.90 2/15/20244,810,000 shares $600.72 million -7.0%N/A4.1 $124.89 1/31/20245,170,000 shares $615.18 million -9.0%N/A4.1 $118.99 1/15/20245,680,000 shares $663.42 million +21.1%N/A3.2 $116.80 12/31/20234,690,000 shares $452.26 million -0.4%N/A2.7 $96.43 12/15/20234,710,000 shares $437.98 million +10.6%N/A2.9 $92.99Is Elon's empire crumbling? (Ad)The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd. Click here to see the Tesla shock that could blindside everyone. 11/30/20234,260,000 shares $346.25 million +0.2%N/A2.8 $81.28 11/15/20234,250,000 shares $355.98 million -4.5%N/A2.9 $83.76 10/31/20234,450,000 shares $299.53 million -8.8%N/A3 $67.31 10/15/20234,880,000 shares $575.64 million +1.2%N/A5.4 $117.96 9/30/20234,820,000 shares $584.28 million +6.6%N/A5.2 $121.22 9/15/20234,520,000 shares $535.17 million -2.0%N/A4.6 $118.40 8/31/20234,610,000 shares $557.86 million +4.1%N/A4.3 $121.01 8/15/20234,430,000 shares $505.37 million -0.5%N/A3.8 $114.08 7/31/20234,450,000 shares $482.34 million -9.9%N/A3.2 $108.39 7/15/20234,940,000 shares $532.70 million -1.0%N/A3.5 $107.84 6/30/20234,990,000 shares $571.45 million +9.7%N/A3.3 $114.52 6/15/20234,550,000 shares $598.83 million +2.9%N/A3.1 $131.61 5/31/20234,420,000 shares $546.31 million +17.9%N/A2.8 $123.60 5/15/20233,750,000 shares $589.46 million -8.5%N/A2.2 $157.19 4/30/20234,100,000 shares $503.36 million -8.5%N/A2.8 $122.77 4/15/20234,480,000 shares $549.38 million -5.1%N/A3.1 $122.63 3/31/20234,720,000 shares $650.56 million -13.2%N/A3.4 $137.83 3/15/20235,440,000 shares $791.36 million -32.7%N/A4 $145.47 2/28/20238,080,000 shares $986.81 million +7.0%N/A7.1 $122.13 2/15/20237,550,000 shares $941.64 million +12.4%N/A8.1 $124.72 1/31/20236,720,000 shares $839.80 million +8.9%N/A7.3 $124.97 1/15/20236,170,000 shares $781.74 million -9.8%N/A6.5 $126.70 12/30/20226,840,000 shares $886.33 million -1.0%N/A7.3 $129.58 12/15/20226,910,000 shares $861.33 million -1.0%N/A7.5 $124.65 11/30/20226,980,000 shares $857.21 million -5.0%N/A6.5 $122.81 11/15/20227,350,000 shares $806.15 million -8.6%N/A7.2 $109.68 10/31/20228,040,000 shares $916.72 million +11.1%N/A7.5 $114.02 10/15/20227,240,000 shares $814.14 million -1.4%N/A6.4 $112.45 9/30/20227,340,000 shares $811.36 million +7.6%N/A6.7 $110.54 9/15/20226,820,000 shares $754.84 million +4.1%N/A6 $110.68 8/31/20226,550,000 shares $716.44 million -4.5%N/A6.7 $109.38 8/15/20226,860,000 shares $748.01 million +34.3%N/A7.2 $109.04 7/31/20225,110,000 shares $474.97 million -4.7%N/A5.5 $92.95 7/15/20225,360,000 shares $448.04 million +2.7%N/A6.8 $83.59 6/30/20225,220,000 shares $391.29 million +4.8%N/A6.7 $74.96 6/15/20224,980,000 shares $321.21 million -0.4%N/A6.7 $64.50 5/31/20225,000,000 shares $364.10 million -2.0%N/A7 $72.82 5/15/20225,100,000 shares $336.45 million +5.6%N/A6.7 $65.97 4/30/20224,830,000 shares $349.31 million -1.2%N/A6.6 $72.32 4/15/20224,890,000 shares $398.29 million -5.4%N/A6.2 $81.45 3/31/20225,170,000 shares $403.88 million -2.5%N/A5.2 $78.12 3/15/20225,300,000 shares $403.70 million -1.1%N/A5.4 $76.17 2/28/20225,360,000 shares $410.63 million -2.2%N/A5.4 $76.61 2/15/20225,480,000 shares $445.80 million -6.8%N/A5.6 $81.35 1/31/20225,880,000 shares $420.83 million +30.1%N/A5.8 $71.57 1/15/20224,520,000 shares $321.37 million -1.3%N/A4.3 $71.10 12/31/20214,580,000 shares $412.43 million -15.0%N/A4.4 $90.05 12/15/20215,390,000 shares $470.71 million -1.1%N/A5.2 $87.33 11/30/20215,450,000 shares $440.41 million +16.5%N/A5.2 $80.81 11/15/20214,680,000 shares $392.56 million +2.0%N/A4.7 $83.88Is Elon's empire crumbling? (Ad)The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd. Click here to see the Tesla shock that could blindside everyone. 10/29/20214,590,000 shares $363.21 million -8.8%N/A4.7 $79.13 10/15/20215,030,000 shares $423.48 million -0.2%N/A5.3 $84.19 9/30/20215,040,000 shares $466.10 million -11.0%6.7%6 $92.48 9/15/20215,660,000 shares $475.72 million -3.6%7.5%7.3 $84.05 8/31/20215,870,000 shares $458.56 million -5.0%7.8%7.5 $78.12 8/13/20216,180,000 shares $494.03 million -2.4%8.2%6.7 $79.94 7/30/20216,330,000 shares $429.05 million -2.5%8.3%6 $67.78 7/15/20216,490,000 shares $443.72 million +0.8%8.5%5.9 $68.37 6/30/20216,440,000 shares $500.65 million -3.3%8.5%5.9 $77.74 6/15/20216,660,000 shares $553.71 million -16.7%8.8%5.8 $83.14 5/28/20217,990,000 shares $604.44 million +4.0%10.5%6.9 $75.65 5/14/20217,680,000 shares $556.88 million +8.0%N/A6.6 $72.51 4/30/20217,110,000 shares $507.73 million -2.2%N/A6.3 $71.41 4/15/20217,270,000 shares $533.84 million -0.7%N/A6.3 $73.43 3/31/20217,320,000 shares $535.09 million +7.3%N/A3.5 $73.10 3/15/20216,820,000 shares $589.73 million -6.8%N/A3.3 $86.47 2/26/20217,320,000 shares $624.03 million +8.9%N/A3.6 $85.25 2/12/20216,720,000 shares $609.97 million -13.3%N/A3.6 $90.77 1/29/20217,750,000 shares $698.51 million -4.3%N/A4.1 $90.13 1/15/20218,100,000 shares $728.19 million +14.6%N/A4.6 $89.90 12/31/20207,070,000 shares $1.21 billion -10.6%N/A5 $171.54 12/15/20207,910,000 shares $1.34 billion -9.1%N/A11.3 $169.54 11/30/20208,700,000 shares $1.21 billion +5.2%N/A12.7 $139.15 11/15/20208,270,000 shares $1.17 billion -6.2%N/A11.6 $141.40 10/30/20208,820,000 shares $1.25 billion -0.6%N/A12.1 $141.49 10/15/20208,870,000 shares $1.29 billion -2.9%N/A13.5 $145.12 9/30/20209,130,000 shares $1.28 billion +0.7%N/A13.1 $140.43 9/15/20209,070,000 shares $1.30 billion -4.1%N/A12.5 $142.80 8/31/20209,460,000 shares $1.39 billion -3.2%N/A12 $146.42 SRPT Short Interest - Frequently Asked Questions What is Sarepta Therapeutics' current short interest? Short interest is the volume of Sarepta Therapeutics shares that have been sold short but have not yet been closed out or covered. As of July 31st, investors have sold 20,950,000 shares of SRPT short. 23.20% of Sarepta Therapeutics' shares are currently sold short. Learn More on Sarepta Therapeutics' current short interest. What is a good short interest ratio for Sarepta Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SRPT shares currently have a short interest ratio of 2.0. Learn More on Sarepta Therapeutics's short interest ratio. Which institutional investors are shorting Sarepta Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Sarepta Therapeutics: Nomura Holdings Inc., Sculptor Capital LP, Hudson Bay Capital Management LP, Group One Trading LLC, BNP Paribas Financial Markets, Balyasny Asset Management L.P., Jane Street Group LLC, Whitebox Advisors LLC, Caption Management LLC, Squarepoint Ops LLC, Qube Research & Technologies Ltd, Walleye Capital LLC, Walleye Trading LLC, Capital Fund Management S.A., Jefferies Financial Group Inc., JPMorgan Chase & Co., Garda Capital Partners LP, Wolverine Asset Management LLC, Sivik Global Healthcare LLC, and Quaker Wealth Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Sarepta Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 23.20% of Sarepta Therapeutics' floating shares are currently sold short. Is Sarepta Therapeutics' short interest increasing or decreasing? Sarepta Therapeutics saw a increase in short interest in July. As of July 31st, there was short interest totaling 20,950,000 shares, an increase of 41.0% from the previous total of 14,860,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Sarepta Therapeutics' short interest compare to its competitors? 23.20% of Sarepta Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Sarepta Therapeutics: CytomX Therapeutics, Inc. (31.82%), Editas Medicine, Inc. (9.58%), Legend Biotech Corporation Sponsored ADR (4.26%), Revolution Medicines, Inc. (8.12%), Rhythm Pharmaceuticals, Inc. (7.23%), Avidity Biosciences, Inc. (13.10%), Nuvalent, Inc. (11.99%), Axsome Therapeutics, Inc. (9.47%), CRISPR Therapeutics AG (26.94%), Merus N.V. (6.44%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), MicroStrategy Incorporated ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Sarepta Therapeutics stock? Short selling SRPT is an investing strategy that aims to generate trading profit from Sarepta Therapeutics as its price is falling. SRPT shares are trading down $0.82 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Sarepta Therapeutics? A short squeeze for Sarepta Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of SRPT, which in turn drives the price of the stock up even further. How often is Sarepta Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SRPT, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies CTMX Short Interest EDIT Short Interest LEGN Short Interest RVMD Short Interest RYTM Short Interest RNA Short Interest NUVL Short Interest AXSM Short Interest CRSP Short Interest MRUS Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SRPT) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access